<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Penbutolol</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01359</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high binding affinity to the 5-hydroxytryptamine receptor 1A with antagonistic effects. This binding characteristic of penbutolol is being investigated for its implications in Antidepressant Therapy. Penbutolol is contraindicated in patients with cardiogenic shock, sinus bradycardia, second and third degree atrioventricular conduction block, bronchial asthma, and those with known hypersensitivity.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01359/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01359/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01359.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01359.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01359.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01359.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01359.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01359">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>(2S)-1-(tert-butylamino)-3-(2-cyclopentylphenoxy)propan-2-ol</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>1-(tert-Butylamino)-3-(o-cyclopentylphenoxy)propan-2-ol</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>2-Propanol, 1-(2-cyclopentylphenoxy)-3-((1,1-dimethylethyl)amino)-, (S)-</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>HOE 893</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>HOE 893D</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Penbutololum</td><td>Latin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Penbutolol sulfate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000137/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000137/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: KTXVDQNRHZQBOR-RSAXXLAASA-N</li>
              <li>Monoisotopic Mass: 389.187208419</li>
              <li>Average Mass: 389.507</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000137">DBSALT000137</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Betapressin</td><td>Hoechst Ltd.</td></tr><tr><td>Levatol</td><td>Schwarz Pharma</td></tr><tr><td>Levatolol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Lobeta</td><td>Sanofi-Aventis</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antihypertensive-agents">Antihypertensive Agents</a></li>
<li><a href="/mesh/adrenergic-beta-antagonists">Adrenergic beta-Antagonists</a></li></ul></td></tr><tr><th>CAS number</th><td>36507-48-9</td></tr><tr><th>Weight</th><td>Average: 291.4284<br>Monoisotopic: 291.219829177</td></tr><tr><th>Chemical Formula</th><td>C<sub>18</sub>H<sub>29</sub>NO<sub>2</sub></td></tr><tr><th>InChI Key</th><td>KQXKVJAGOJTNJS-HNNXBMFYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C18H29NO2/c1-18(2,3)19-12-15(20)13-21-17-11-7-6-10-16(17)14-8-4-5-9-14/h6-7,10-11,14-15,19-20H,4-5,8-9,12-13H2,1-3H3/t15-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">tert-butyl[(2S)-3-(2-cyclopentylphenoxy)-2-hydroxypropyl]amine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB01359.gif?1371147078">show</a>(49.2 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenol Ethers</td></tr><tr><th>Direct parent</th><td>Phenol Ethers</td></tr><tr><th>Alternative parents</th><td>Alkyl Aryl Ethers; Secondary Alcohols; 1,2-Aminoalcohols; Polyamines; Dialkylamines</td></tr><tr><th>Substituents</th><td>alkyl aryl ether; 1,2-aminoalcohol; secondary alcohol; secondary amine; ether; secondary aliphatic amine; polyamine; amine; alcohol; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Penbutolol is indicated in the treatment of mild to moderate arterial hypertension. It may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.Penbutolol is contraindicated in patients with cardiogenic shock, sinus bradycardia, second and third degree atrioventricular conduction block, bronchial asthma, and those with known hypersensitivity.</td></tr><tr><th>Pharmacodynamics</th><td>Penbutolol is a &#223;-1, &#223;-2 (nonselective) adrenergic receptor antagonist. Experimental studies showed a dose-dependent increase in heart rate in reserpinized (norepinephrine-depleted) rats given penbutolol intravenously at doses of 0.25 to 1.0 mg/kg, suggesting that penbutolol has some intrinsic sympathomimetic activity. In human studies, however, heart rate decreases have been similar to those seen with propranolol.</td></tr><tr><th>Mechanism of action</th><td>Penbutolol acts on the &#946;1 adrenergic receptors in both the heart and the kidney. When &#946;1 receptors are activated by catecholamines, they stimulate a coupled G protein that leads to the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). The increase in cAMP leads to activation of protein kinase A (PKA), which alters the movement of calcium ions in heart muscle and increases the heart rate. Penbutolol blocks the catecholamine activation of &#946;1 adrenergic receptors and decreases heart rate, which lowers blood pressure.</td></tr><tr><th>Absorption</th><td>&gt;90%.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>80-98% bound to plasma proteins. Extensively bound to Alpha-1-acid glycoprotein 1. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Metabolized in the liver by hydroxylation and glucuroconjugation forming a glucuronide metabolite and a semi-active 4-hydroxy metabolite. </p></td></tr><tr><th>Route of elimination</th><td>The metabolites are excreted principally in the urine.</td></tr><tr><th>Half life</th><td>Plasma= approximately 5h
Conjugated= approximately 20h in healthy persons, 25h in healthy elderly persons, and 100h in patients on renal dialysis. </td></tr><tr><th>Clearance</th><td><p>Approximately 90% of the metabolites are excreted in the urine.</p></td></tr><tr><th>Toxicity</th><td>Symptoms of overdose include drowsiness, vertigo, headache, and atriventricular block.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Penbutolol Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9935</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.747</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5961</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6827</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7493</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7789</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8696</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7898</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.8919</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6339</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9107</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8899</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.8932</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8309</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.7132</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8317
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8643
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9927
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.3931 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9436
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.5704
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Schwarz pharma inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Schwarz Pharma Inc.</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>20 mg, yellow, oval. </td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01223">Aminophylline</a></td><td>Antagonism of action and increased effect of theophylline</td></tr><tr><td><a href="/drugs/DB00672">Chlorpropamide</a></td><td>The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00575">Clonidine</a></td><td>Increased hypertension when clonidine stopped</td></tr><tr><td><a href="/drugs/DB00390">Digoxin</a></td><td>Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.</td></tr><tr><td><a href="/drugs/DB00320">Dihydroergotamine</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00280">Disopyramide</a></td><td>The beta-blocker, penbutolol,  may increase the toxicity of disopyramide.</td></tr><tr><td><a href="/drugs/DB00668">Epinephrine</a></td><td>Hypertension, then bradycardia</td></tr><tr><td><a href="/drugs/DB00696">Ergotamine</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB01288">Fenoterol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB00983">Formoterol</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB01120">Gliclazide</a></td><td>The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01016">Glyburide</a></td><td>The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01050">Ibuprofen</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB00328">Indomethacin</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB00047">Insulin Glargine</a></td><td>The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00281">Lidocaine</a></td><td>Penbutolol increases the volume of distribution of lidocaine in normal subjects. This could result in a requirement for higher loading doses of lidocaine.</td></tr><tr><td><a href="/drugs/DB00968">Methyldopa</a></td><td>Possible hypertensive crisis</td></tr><tr><td><a href="/drugs/DB00247">Methysergide</a></td><td>Ischemia with risk of gangrene</td></tr><tr><td><a href="/drugs/DB00816">Orciprenaline</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB01303">Oxtriphylline</a></td><td>Antagonism of action and increased effect of theophylline</td></tr><tr><td><a href="/drugs/DB00236">Pipobroman</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB00554">Piroxicam</a></td><td>Risk of inhibition of renal prostaglandins</td></tr><tr><td><a href="/drugs/DB00457">Prazosin</a></td><td>Risk of hypotension at the beginning of therapy</td></tr><tr><td><a href="/drugs/DB00912">Repaglinide</a></td><td>The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01162">Terazosin</a></td><td>Increased risk of hypotension. Initiate concomitant therapy cautiously.</td></tr><tr><td><a href="/drugs/DB00871">Terbutaline</a></td><td>Antagonism</td></tr><tr><td><a href="/drugs/DB00277">Theophylline</a></td><td>Antagonism of action and increased effect of theophylline</td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>